Abstract
The small GTP-binding protein, RhoA, and its downstream effector protein, rho-kinase, have been implicated in the pathogenesis of a number of cardiovascular diseases. The activation of rho-kinase is involved in the development of increased vascular tone, endothelial dysfunction, inflammation, and restenosis; and that the inhibition of rho-kinase has been shown to have a beneficial effect in a variety of cardiovascular disorders. It is our hypothesis that rho-kinase inhibitors promote vasodilation independent of the mechanism that increases vasoconstrictor tone and moreover, the RhoA/rho-kinase pathway has a role in the regulation of smooth muscle tone under physiological conditions. The objective of this review is to improve our current understanding of the role of RhoA/rho-kinase pathway in the regulation of vasoconstrictor tone and the use of rho-kinase inhibitors in the treatment of cardiovascular disorders with an emphasis on pulmonary hypertension.
Keywords: Intracellular signaling peptides and proteins, protein kinases, RhoA/rho-kinase pathway, muscle, smooth, vascular, pulmonary hypertension, pulmonary vascular bed, systemic vascular bed, signal transduction, inhibitors/pharmacology, cardiovascular diseases, fasudil, HA-1077, Y-27632
Current Drug Discovery Technologies
Title: The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Volume: 6 Issue: 1
Author(s): Bobby D. Nossaman and Philip J. Kadowitz
Affiliation:
Keywords: Intracellular signaling peptides and proteins, protein kinases, RhoA/rho-kinase pathway, muscle, smooth, vascular, pulmonary hypertension, pulmonary vascular bed, systemic vascular bed, signal transduction, inhibitors/pharmacology, cardiovascular diseases, fasudil, HA-1077, Y-27632
Abstract: The small GTP-binding protein, RhoA, and its downstream effector protein, rho-kinase, have been implicated in the pathogenesis of a number of cardiovascular diseases. The activation of rho-kinase is involved in the development of increased vascular tone, endothelial dysfunction, inflammation, and restenosis; and that the inhibition of rho-kinase has been shown to have a beneficial effect in a variety of cardiovascular disorders. It is our hypothesis that rho-kinase inhibitors promote vasodilation independent of the mechanism that increases vasoconstrictor tone and moreover, the RhoA/rho-kinase pathway has a role in the regulation of smooth muscle tone under physiological conditions. The objective of this review is to improve our current understanding of the role of RhoA/rho-kinase pathway in the regulation of vasoconstrictor tone and the use of rho-kinase inhibitors in the treatment of cardiovascular disorders with an emphasis on pulmonary hypertension.
Export Options
About this article
Cite this article as:
Nossaman D. Bobby and Kadowitz J. Philip, The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension, Current Drug Discovery Technologies 2009; 6 (1) . https://dx.doi.org/10.2174/157016309787581057
DOI https://dx.doi.org/10.2174/157016309787581057 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice
Protein & Peptide Letters Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research The Effectiveness of Nurse- and Pharmacist-Directed Care in Diabetes Disease Management:A Narrative Review
Current Diabetes Reviews PPARγ-targeting Potential for Radioprotection
Current Drug Targets An Evidence-Based Systematic Review of Stevia by the Natural Standard Research Collaboration
Cardiovascular & Hematological Agents in Medicinal Chemistry Evolving Concepts Concerning Cardiac β-Adrenoceptor Function in Heart Failure
Current Pharmaceutical Design Editorial [Hot topic: Current Topics on Hypolipidaemic Therapy and Cardiovascular Risk Assessment (Guest Editors: Evangelos C. Rizos and Moses S. Elisaf)]
Current Vascular Pharmacology Comparative Evaluation of Conventional and Novel Extracts of Stem Bark of Terminalia arjuna for Antihypertensive Activity in BSO Induced Oxidative Stress based Rat Model
Current Pharmaceutical Biotechnology Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Interstitial Lung Disease in Systemic Sclerosis: Pathophysiology, Current and New Advances in Therapy
Inflammation & Allergy - Drug Targets (Discontinued) Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Serum Uric Acid Level as a Predictive Biomarker of Gestational Hypertension Severity; A Prospective Observational Case-Control Study
Reviews on Recent Clinical Trials Neutrophil Cell Count is Related to Hypertension in Workers: A Cross- Sectional Study
Vascular Disease Prevention (Discontinued) Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Current Treatment Strategies for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Superoxide Dismutases: Anti- Versus Pro- Oxidants?
Anti-Cancer Agents in Medicinal Chemistry